AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 80_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 2_CD Share_NN of_IN turnover_NN and_CC operating_VBG profits_NNS of_IN joint_JJ venture_NN 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Share_NN of_IN joint_JJ venture_NN turnover_NN 227 208 191_CD There_EX was_VBD no_DT share_NN of_IN operating_VBG profits_NNS of_IN the_DT joint_JJ venture_NN attributable_JJ to_TO the_DT Group_NNP ._.
On_IN 1_CD September_NNP 2004_CD ,_, the_DT Group_NNP disposed_VBD of_IN its_PRP$ interest_NN in_IN the_DT ordinary_JJ share_NN capital_NN of_IN Advanta_NNP BV_NNP ,_, its_PRP$ only_RB major_JJ joint_JJ venture_NN ._.
The_DT profit_NN on_IN disposal_NN is_VBZ shown_VBN in_IN Note_NN 3_CD ._.
3_CD Exceptional_JJ items_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Accrual_NNP related_VBN to_TO Zoladex_NNP investigation_NN 350_CD Exceptional_JJ items_NNS included_VBN in_IN operating_NN profit_NN 350_CD Profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN 219_CD Total_JJ exceptional_JJ items_NNS before_IN taxation_NN 219_CD 350_CD Net_JJ taxation_NN credit_NN 67_CD Total_JJ exceptional_JJ items_NNS after_IN taxation_NN 286_CD 350_CD The_DT profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN relates_VBZ to_TO the_DT disposal_NN of_IN the_DT Groups_NNS interest_NN in_IN the_DT ordinary_JJ share_NN capital_NN of_IN Advanta_NNP BV_NNP ._.
There_EX is_VBZ a_DT tax_NN credit_NN of_IN $_$ 9m_CD arising_VBG on_IN costs_NNS associated_VBN with_IN the_DT disposal_NN ._.
As_IN set_VBN out_RP in_IN more_JJR detail_NN in_IN Note_NN 5_CD ,_, the_DT Company_NNP announced_VBD on_IN 20_CD June_NNP 2003_CD a_DT settlement_NN of_IN the_DT US_NNP Department_NNP of_IN Justice_NNP investigation_NN into_IN the_DT US_NNP sales_NNS and_CC marketing_NN practices_NNS for_IN Zoladex_NNP goserelin_NN acetate_NN implant_VBP ._.
Negotiations_NNS towards_IN this_DT settlement_NN were_VBD sufficiently_RB advanced_VBN to_TO recognize_VB an_DT exceptional_JJ charge_NN of_IN $_$ 350m_CD at_IN 31_CD December_NNP 2002_CD ._.
An_DT agreement_NN has_VBZ been_VBN reached_VBN with_IN the_DT US_NNP tax_NN authorities_NNS that_WDT $_$ 170m_CD of_IN the_DT settlement_NN is_VBZ deductible_JJ for_IN tax_NN purposes_NNS ._.
Consequently_RB an_DT exceptional_JJ tax_NN credit_NN of_IN $_$ 58m_CD has_VBZ been_VBN recorded_VBN in_IN 2004_CD ._.
These_DT items_NNS are_VBP regarded_VBN as_IN exceptional_JJ due_JJ to_TO their_PRP$ unusual_JJ and_CC non-recurring_JJ nature_NN ._.
There_EX were_VBD no_DT exceptional_JJ items_NNS in_IN 2003_CD ._.
4_CD Net_JJ interest_NN 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Interest_NN receivable_NN and_CC similar_JJ income_NN from_IN investments_NNS Securities_NNPS 10_CD 21_CD 21_CD Short_JJ term_NN deposits_NNS 81_CD 75_CD 90_CD Gain_NN on_IN disposal_NN of_IN interest_NN rate_NN swap_NN 30_CD Exchange_NNP gains_NNS 15_CD 19_CD 6_CD 136 115 117_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS Loan_NN interest_NN 30_CD 7_CD 10_CD Interest_NN on_IN short_JJ term_NN borrowings_NNS and_CC other_JJ financing_NN costs_NNS 16_CD 16_CD 51_CD Discount_NNP on_IN liability_NN 3_CD 10_CD Exchange_NNP losses_NNS 16_CD 46_CD 26_CD 87_CD Net_JJ interest_NN receivable_NN 90_CD 89_CD 30_CD
